Internal Study | Retro-ARV | HIV | SNDS
Rétro-ARV is a study aiming to investigate the treatment history and care pathways of HIV patients in France. The goal is to identify therapeutic changes over the past ten years and document the types and durations of treatments received or taken by HIV-positive individuals.
In France, around 170,000 people live with HIV, with an incidence of approximately 6,000 new cases per year. In 2016, nearly 74% of people living with HIV were stabilized, with controlled viral loads (in this publication, <200 copies/ml). This rate reaches 97% in the treated population.
Once virological success is achieved (viral load < 50 copies/ml), antiretroviral treatment modification may be helpful or necessary in various circumstances and with different goals. The aim is to individualize treatment to improve tolerance and/or ease of administration while maintaining immunovirological efficacy. This may include:
-
improving patient quality of life, for example by reducing the number of doses and/or pills taken,
-
correcting or preventing side effects, including cardiovascular, metabolic, renal, or skeletal issues,
-
correcting or preventing drug interactions, especially when a new medication is introduced.
The Rétro-ARV study covered 1,258 individuals, representing an estimated total prevalence of 128,000 cases. The male-to-female ratio was 69%, consistent with the data from the French Court of Auditors, which stated that in 2017, men represented 66% of new HIV diagnoses, a proportion that has remained stable since 2010.
Role of Alsinova: Alsinova designed and conducted this study based on the EGB (French general sample of health insurance beneficiaries) in order to assess the duration of the last reimbursed antiretroviral treatment and to specifically describe the percentage of people who experienced treatment relief.